Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of LY2835219 in Previously Treated HR+, HER2- Metastatic Breast Cancer
2013-005548-27Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in breast cancer, sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate (ORR). Started Apr 2014; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-005548-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005548-27.